Health · Medicine

FDA Approves First Oral PCSK9 Inhibitor — A New Era for Cholesterol Treatment

For millions of adults who struggle with high cholesterol, the standard of care has long been daily statins — and for those who need more, weekly or biweekly injections of PCSK9 inhibitors. That changed on July 16, 2026, when the FDA approved Lipfendra (enlicitide), the first once-daily oral pill in this powerful class of cholesterol-lowering drugs.

High cholesterol affects roughly 38 percent of American adults. Statins work well for many, but some patients cannot tolerate them, and others do not reach their target LDL levels even with maximum doses. For them, PCSK9 inhibitors — injectable drugs that block a protein interfering with the liver's ability to clear LDL from the blood — have been a powerful but inconvenient option. Lipfendra changes that by delivering the same mechanism in a 20-milligram tablet taken once a day.

How the new pill works

The key fact: blocking PCSK9 unlocks the liver's natural cholesterol clearance

PCSK9 is a protein that binds to LDL receptors on liver cells and directs them to be destroyed. Fewer receptors mean less LDL is cleared from the bloodstream, and levels rise. Lipfendra inhibits PCSK9, preventing it from degrading those receptors. The result is a higher density of functioning LDL receptors on the liver surface, which actively pulls LDL cholesterol out of the blood. Clinical trials showed that patients taking Lipfendra achieved LDL reductions comparable to those seen with injectable PCSK9 inhibitors, with a similar safety profile.

Three things worth knowing

First oral in its class: Until now, all PCSK9 inhibitors — Repatha and Praluent — required injection every one to four weeks. Lipfendra is the first oral option, removing the needle barrier that causes many eligible patients to decline treatment.
Approved for high-risk groups: The FDA approved it for adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH), a genetic condition that causes dangerously high LDL levels regardless of lifestyle.
Two phase 3 trials confirmed efficacy: The CORALreef Lipids and CORALreef HeFH trials enrolled over 1,400 patients and showed consistent LDL reductions across diverse populations, supporting the approval decision.

Why this matters beyond convenience

Cardiovascular disease remains the leading cause of death globally. Despite widespread statin use, a significant portion of high-risk patients remains undertreated, often because of statin intolerance, fear of needles, or lack of access to injectable biologics. An oral PCSK9 inhibitor that can be prescribed like any other daily pill has the potential to close that treatment gap. For patients with heterozygous familial hypercholesterolemia — who have been fighting high cholesterol since childhood — an oral option may be life-changing.

The development also signals a broader shift in the pharmaceutical industry. For years, biologic drugs — large, injectable protein-based therapies — dominated the most effective treatment classes. Lipfendra proves that small-molecule oral drugs can match their potency, at a fraction of the manufacturing complexity and with dramatically better patient acceptance.